Paralos Bio
1 known investors
Paralos is developing a modular M13 phage drug delivery platform that creates phage-drug conjugates to concentrate therapeutic payloads at specific targets. The platform pairs programmable target binding with payload presentation to localize drug exposure and engineer delivery around the therapeutic window.
Investors · 1
Frequently asked questions
- What does Paralos Bio do?
- Paralos is developing a modular M13 phage drug delivery platform that creates phage-drug conjugates to concentrate therapeutic payloads at specific targets. The platform pairs programmable target binding with payload presentation to localize drug exposure and engineer delivery around the therapeutic window.
- Who are Paralos Bio's investors?
- Paralos Bio's investors include Carbon Silicon.